At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and ≥10% weight loss In ...
Taltz is a brand-name prescription medication known as a biologic. Its active ingredient is ixekizumab. Taltz (ixekizumab) is a subcutaneous (below the skin) injection. A doctor or another healthcare ...
On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...
It’s not known whether Taltz (ixekizumab) is safe to use while pregnant or breastfeeding. Certain factors may determine whether you should use the drug during this time. If you may be or can become ...
Eli Lilly and Co. (NYSE: LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...
Adverse events in participants treated with concomitant administration of Taltz and Zepbound were generally mild to moderate, and the types of adverse events were consistent with the known safety ...
The most common adverse events occurring in ≥5% of participants were nausea, diarrhea, constipation and injection site reactions in the concomitant treatment arm, and injection site reactions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results